Metastatic Colorectal Cancers Recruiting Phase 2 Trials for Oxaliplatin (DB00526)

Back to Metastatic Colorectal Cancers

Also known as: Metastatic Colorectal Cancer / Colorectal Cancer Metastatic / Cancer - Metastatic Colorectal / Metastatic Colorectal Cancer (MCRC) / Colorectal Cancer, Metastatic / Secondary malignant neoplasm of colon and/or rectum (disorder) / Secondary malignant neoplasm of large intestine (disorder)

Indication	Status	Phase
DBCOND0063579 (Metastatic Colorectal Cancers)	Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT04430985	FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer	Treatment	Fluorouracil (DB00544) Leucovorin (DB00650) Nivolumab (DB09035) Oxaliplatin (DB00526)
NCT04513951	AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients	Treatment	Avelumab (DB11945) Cetuximab (DB00002) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT04034459	FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC	Treatment	Bevacizumab (DB00112) Cetuximab (DB00002) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT04097444	CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC	Treatment	Bevacizumab (DB00112) Capecitabine (DB01101) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT01531595	Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal Cancer	Treatment	Bevacizumab (DB00112) Capecitabine (DB01101) Irinotecan (DB00762) Oxaliplatin (DB00526)
NCT01991873	Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer	Treatment	Leucovorin (DB00650) Oxaliplatin (DB00526) Panitumumab (DB01269)
NCT02980510	Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients	Treatment	Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526) Panitumumab (DB01269)
NCT03117972	Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels	Treatment	Bevacizumab (DB00112) Capecitabine (DB01101) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT04245865	Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer	Treatment	Bevacizumab (DB00112) Capecitabine (DB01101) Fluorouracil (DB00544) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT03388190	METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin	Treatment	Fluorouracil (DB00544) Leucovorin (DB00650) Nivolumab (DB09035) Oxaliplatin (DB00526)
NCT03792269	Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC	Treatment	Capecitabine (DB01101) Irinotecan (DB00762) Oxaliplatin (DB00526)
NCT04169347	FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer	Treatment	Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526) Panitumumab (DB01269)
NCT03164655	Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network	Treatment	Bevacizumab (DB00112) Cetuximab (DB00002) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526) Panitumumab (DB01269)